|
Cartilage Extract to Treat Lung Cancer
Untitled Document
Name of the Trial
Phase III Randomized Study of Induction Platinum-Based Chemotherapy and Radiotherapy
with or without AE-941 (Neovastat) in Patients With Unresectable Stage IIIA
or IIIB Non-Small Cell Lung Cancer (MDA-ID-99303). See
the protocol summary.
Principal Investigator
 |
Dr. Charles Lu
Principal Investigator |
Dr. Charles Lu of the University of Texas M.D. Anderson Cancer Center.
Why This Trial Is Important
Patients who have advanced non-small cell lung cancer (NSCLC) that cannot be
removed surgically (unresectable) are often treated with platinum-based chemotherapy
agents and radiation therapy in an attempt to prolong their survival.
Like other solid tumors, NSCLCs require a constant supply of blood to grow.
Drugs that block the formation of new blood vessels to tumors are called angiogenesis
inhibitors. Such drugs may help cancer patients survive longer. In this trial,
researchers are studying the ability of AE-941 (Neovastat®), a liquid extract
of shark cartilage that has angiogenesis inhibitor activity, to improve the
survival of patients with unresectable NSCLC when given in combination with
traditional chemotherapy and radiation therapy.
"What is different about this study is that we are using a standardized
extract from cartilage instead of a drug devised from a single molecule,"
said Dr. Lu. "Thus, Neovastat may offer a combination of molecules that
work together to inhibit angiogenesis."
"Data from animal studies support the hypothesis that this extract has
antiangiogenic activity and that it may inhibit certain enzymes involved in
cancer cell metastasis, such as matrix metalloproteinases 2, 9, and 12,"
Dr. Lu added.
Contact Information
This clinical trial is no longer recruiting new patients. To find other clinical
trials for lung cancer, search the NCI's database of
clinical trials or call the NCI's Cancer Information Service at 1-800-4-CANCER
(1-800-422-6237). The call is toll-free and completely confidential.
Published Results
Lu C, Komaki R, Herbst RS, et al.: A phase III study of AE-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non-small cell lung cancer (NSCLC) (NCI T99-0046, RTOG 02-70, MDA 99-303): an interim report of toxicity and response. [Abstract] J Clin Oncol 23 (Suppl 16): A-7144, 656s, 2005.
 Back to Top |
